A review of contrast-enhanced ultrasound using SonoVue® and Sonazoid™ in non-hepatic organs

Qing Zhang; Xiaowen Liang; Yanfen Zhang; Hongjun Nie; Zhiyi Chen

doi:10.1016/j.ejrad.2023.111060

A review of contrast-enhanced ultrasound using SonoVue® and Sonazoid™ in non-hepatic organs

Eur J Radiol. 2023 Oct:167:111060. doi: 10.1016/j.ejrad.2023.111060. Epub 2023 Aug 22.

Authors

Qing Zhang¹, Xiaowen Liang², Yanfen Zhang³, Hongjun Nie³, Zhiyi Chen⁴

Affiliations

¹ Institution of Medical Imaging, The Affiliated Changsha Central Hospital, Hengyang Medical School, University of South China, Changsha, China; Institution of Medical Imaging, University of South China, Hengyang, China; The Seventh Affiliated Hospital, Hengyang Medical School, University of South China, Changsha, China.
² Institution of Medical Imaging, The Affiliated Changsha Central Hospital, Hengyang Medical School, University of South China, Changsha, China; Institution of Medical Imaging, University of South China, Hengyang, China.
³ Department of Ultrasound, The Affiliated Changsha Central Hospital, Hengyang Medical School, University of South China, Changsha, China.
⁴ Institution of Medical Imaging, The Affiliated Changsha Central Hospital, Hengyang Medical School, University of South China, Changsha, China; Institution of Medical Imaging, University of South China, Hengyang, China. Electronic address: zhiyi_chen@usc.edu.cn.

PMID: 37657380
DOI: 10.1016/j.ejrad.2023.111060

Abstract

Contrast-enhanced ultrasound (CEUS) is a dependable modality for the diagnosis of various clinical conditions. A judicious selection of ultrasound contrast agent (UCA) is imperative for optimizing imaging and improving diagnosis. Approved UCAs for imaging the majority of organs include SonoVue, a pure blood agent, and Sonazoid, which exhibits an additional Kupffer phase. Despite the fact that the two UCAs are increasingly being employed, there is a lack of comparative reviews between the two agents in different organs diseases. This review represents the first attempt to compare the two UCAs in non-hepatic organs, primarily including breast, thyroid, pancreas, and spleen diseases. Through comparative analysis, this review provides a comprehensive and objective evaluation of the performance characteristics of SonoVue and Sonazoid, with the aim of offering valuable guidance for the clinical application of CEUS. Overall, further clinical evidences are required to compare and contrast the dissimilarities between the two UCAs in non-hepatic organs, enabling clinicians to make an appropriate selection based on actual clinical applications.

Keywords: Contrast-enhanced ultrasound; Non-hepatic organs; Sonazoid; SonoVue; Ultrasound contrast agent.

Publication types

Review

MeSH terms

Humans
Oxides*
Sulfur Hexafluoride*
Ultrasonography

Substances

contrast agent BR1
Sonazoid
Sulfur Hexafluoride
Oxides